Comparative Pharmacology
Head-to-head clinical analysis: DERMA SMOOTHE FS versus FLUOTREX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DERMA SMOOTHE FS versus FLUOTREX.
DERMA-SMOOTHE/FS vs FLUOTREX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluocinolone acetonide is a corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to inhibit pro-inflammatory cytokines and reduce inflammation, vasodilation, and edema.
The active metabolite of FLUOTREX, 5-fluorouracil (5-FU), inhibits thymidylate synthase, leading to depletion of thymidine triphosphate and inhibition of DNA synthesis. Additionally, it incorporates into RNA, disrupting RNA function.
Apply topically as a thin film to affected areas twice daily. Maximum weekly dose should not exceed 60 g.
20 mg/m2 intramuscularly once weekly, not to exceed 30 mg/m2 per week.
None Documented
None Documented
Terminal elimination half-life: 24-36 hours (systemic absorption after topical application); clinical context: prolonged with hepatic impairment.
Terminal elimination half-life is approximately 3-5 hours in adults with normal renal function. In patients with renal impairment, half-life may be prolonged up to 10-15 hours, necessitating dose adjustment.
Primarily renal (90%) as inactive metabolites; <5% unchanged. Biliary/fecal excretion accounts for <10%.
Primarily renal excretion as unchanged drug (approximately 60-70% of administered dose), with the remainder eliminated via biliary/fecal routes (20-30%) and minor metabolic clearance.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid